Abcellera Biologics Inc. Stock Price, News & Analysis

AbCellera (Nasdaq: ABCL) will present at the Society for Immunotherapy of Cancer's 37th Annual Meeting from November 8 to 12, 2022. The company’s VP of Translational Research, Bo Barnhart, emphasized the potential of T-cell engagers in oncology, highlighting advances in their CD3 panel and T-cell engager program. The presentation titled 'Streamlining T-cell engager development' is scheduled for November 11, showcasing AbCellera's bispecific engineering technology aimed at overcoming challenges in cancer treatment.

AbCellera (Nasdaq: ABCL) has commenced the second phase of its global headquarters expansion in Vancouver, Canada, with a new 380,000-square-foot tech campus. This facility will enhance lab and office capabilities to support the company's objectives in antibody-based medicine development. The expansion aims to accommodate its growing workforce of over 450 employees and advance its integrated solutions for biopharma partners. The completion of this facility is planned for 2025, following the first phase scheduled for late 2023.

AbCellera (Nasdaq: ABCL) reported Q2 2022 financial results with total revenue of $46 million, a significant increase from $28 million in Q2 2021. The company incurred a net loss of $7 million, up from $2 million in the previous year. Notably, four new programs were initiated, increasing the total program starts by 47% year-over-year to 88. Additionally, AbCellera added six new programs under contract, bringing the total to 164. R&D expenses grew to $26.7 million, while cash reserves amounted to $1.022 billion.

AbCellera (Nasdaq: ABCL) has partnered with Atlas Venture to discover therapeutic antibodies for up to three drug targets. The collaboration allows a stealth-stage company backed by Atlas to develop and commercialize these antibodies, leveraging AbCellera's advanced technology for faster drug discovery. Under the agreement, AbCellera will receive research payments and potential milestone payments, enhancing its revenue generating capabilities. Both companies emphasize a commitment to create impactful medicines efficiently and effectively.

AbCellera (Nasdaq: ABCL) has announced a multi-year partnership with Versant Ventures to discover therapeutic antibodies for various targets. This collaboration builds on previous successful partnerships, enabling three stealth-stage companies under Versant. AbCellera will receive research payments and potential milestone payments, along with royalties on product sales. The partnership aims to enhance the capabilities of small biotech firms, improving their efficiency in developing antibody therapeutics.

AbCellera (Nasdaq: ABCL) will report its second quarter 2022 financial results on August 9, 2022, with an earnings conference call at 2:00 p.m. PT. Investors can access the webcast via the company's Investor Relations website. AbCellera is a technology firm specializing in antibody development, collaborating with various drug developers to enhance drug discovery and reduce costs. Further details about the company can be found on its official website.

AbCellera (NASDAQ: ABCL) announced a modified purchase agreement with Eli Lilly to supply 150,000 doses of bebtelovimab to the U.S. government for approximately $275 million. This supply is set to meet current demand through late August 2022, with deliveries starting immediately. An additional option for 350,000 doses is available until September 14, 2022. Bebtelovimab retains neutralization efficacy against prevalent Omicron variants in the U.S. AbCellera's efforts led to the development of significant COVID-19 treatments, including bamlanivimab and bebtelovimab, showcasing its capabilities in pandemic response.

AbCellera (Nasdaq: ABCL) reported total revenues of $317 million for Q1 2022, up from $203 million a year earlier, with net earnings of $168.6 million (or $0.59 per basic share) compared to $117.2 million (or $0.43 per basic share) in Q1 2021. The company initiated six new drug discovery programs, bringing the cumulative total to 84, a 56% increase from the previous year. R&D expenses rose to $26.4 million, reflecting increased investments in their platform. The company ended the quarter with $786.1 million in cash and equivalents.

AbCellera (NASDAQ: ABCL) has announced an expansion of its collaboration with Empirico Inc., increasing their targets from five to seven. The partnership utilizes Empirico's Precision Insights Platform for drug target discovery and AbCellera's technology for identifying lead candidate antibodies. The companies successfully identified a lead candidate in under 12 months. The new agreement allows AbCellera to co-develop therapeutic programs, maintaining up to a 50% ownership stake in the resulting antibodies, although financial terms were not disclosed.